Described herein are macrocyclic compounds of Formula (I), which can inhibit kinases such as EGFR, including mutant forms such as T790M EGFR mutants. Also described herein are pharmaceutical compositions comprising a compound of Formula (I), or any pharmaceutically acceptable form thereof, processes for their preparation, and use in therapy for the prevention or treatment of cancer. In particular, compounds described herein can be effective for treating EGFR-driven cancers including non-small cell lung cancer (NSCLC).
本文描述了一些公式(I)的大环化合物,可以抑制
EGFR等激酶,包括突变形式,如T790M
EGFR突变体。本文还描述了包括公式(I)化合物或其任何药学上可接受的形式的制药组合物,其制备过程以及在预防或治疗癌症方面的应用。特别是,本文所描述的化合物可有效治疗
EGFR驱动的癌症,包括非小细胞肺癌(NSCLC)。